Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public a quick fix and a path to losing excess weight or resolving their diabetic issues. GLP-1 drugs are revolutionizing medicine and the treatment of patients with diabetes, obesity, and other disorders associated with obesity.
With the growing demand of these drugs, pharmaceutical companies, health care providers, telemedicine companies, and pharmaceutical compounders are facing new challenges with GLP-1s. Organizations need to know how to navigate a complex set of issues, including patent considerations, regulatory issues, lawsuits, and M&A activity.
Foley’s Health Care & Life Sciences and Innovative Technology sectors invite you to join us for a webinar on how your organization can navigate the crossroads of GLP-1s and prepare for this evolving landscape.
This webinar will explore the following GLP-1 topics:
- An inside look on the U.S. Food & Drug Administration’s (FDA) perspective
- How to prepare and secure your patents and safeguard your intellectual property
- The do’s and don’ts of mergers and acquisitions
- Litigation trends
- Clinical trial considerations
Please click here to watch the recording.
CLE
認定申請は、カリフォルニア州、コロラド州、フロリダ州、イリノイ州、ニューヨーク州、テキサス州、ユタ州、バージニア州、ウィスコンシン州に対して行われます。
Foley & Lardner LLP は、カリフォルニア州、コロラド州、イリノイ州、ニューヨーク州、テキサス州、ユタ州の MCLE プロバイダーとして承認されています。
ニューヨーク州の CLE 単位取得のため、このプログラムは、新規に弁護士資格を取得した弁護士にも、経験豊富な弁護士にも適しています。
受講証明書は、プログラム終了後約 8 週間後に、対象となる参加者に電子メールで配布されます。